GlassScriptPhysician profile
Luis Alberto Rosas
NPI 1720263817
$80,170.14
in general payments reported to CMS, 2019-2025
14 companies · $5,879 in 2025
The $5,879 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $3,971 · 2021: $6,923 · 2022: $21K · 2023: $14K · 2024: $7,689 · 2025: $5,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $7,838 · Food and Beverage: $2,156 · Travel and Lodging: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,875.00 |
| Consulting Fee | $7,837.50 |
| Food and Beverage | $2,156.04 |
| Travel and Lodging | $813.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,739.09 | 2021-2025 | Teflaro, Avycaz, Dalvance |
| Allergan, INC. | $18,509.51 | 2019-2021 | |
| Melinta Therapeutics, LLC | $14,302.34 | 2019-2025 | Rezzayo, Kimyrsa |
| Modernatx, INC. | $7,837.50 | 2023 | Moderna Covid-19 Vaccine |
| Paratek Pharmaceuticals, INC. | $3,658.62 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $1,539.23 | 2019 | |
| Lilly USA, LLC | $452.29 | 2024-2025 | Mounjaro |
| Smith+Nephew, INC. | $376.99 | 2022-2024 | Grafix Pl |
| Insmed, INC. | $244.79 | 2023-2024 | Arikayce |
| Janssen Products, LP | $231.42 | 2019 | |
| Intuitive Surgical, INC. | $97.23 | 2020 | |
| Abbott Laboratories | $85.70 | 2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $62.40 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $33.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Rosas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.